CADTH | Evidence Driven
CADTH | Evidence Driven

icatibant

Details

Files
Generic Name:
icatibant
Project Status:
Active
Therapeutic Area:
Hereditary Angioedema
Call for patient/clinician input open:
Brand Name:
NA
Project Line:
Reimbursement Review
Project Number:
SX0849-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Drug Plan Initiated
Fee Schedule:
Pending
Indications:
​Acute attacks of Type III Hereditary Angioedema (HAE nC1-INH).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Submission receivedMarch 18, 2024

Files

Proposed Project Scope View PDF
Last Updated : March 18, 2024